(Q37888716)

24 August 2017

1 reference

title

Managing multiple myeloma in the elderly: are we making progress? (English)

1 reference

24 August 2017

1 reference

Hang Quach

1

1 reference

24 August 2017

H Miles Prince

series ordinal

2

1 reference

24 August 2017

Andrew Spencer

series ordinal

3

1 reference

24 August 2017

language of work or name

1 reference

1 June 2011

1 reference

Expert Review of Hematology

24 August 2017

published in

1 reference

24 August 2017

volume

4

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

301-315

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

24 August 2017

cites work

1 reference

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

21 January 2018

1 reference

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

21 January 2018

1 reference

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

21 January 2018

1 reference

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

21 January 2018

1 reference

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

21 January 2018

1 reference

Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic

21 January 2018

1 reference

Cancer Incidence and Mortality Trends in the United States: 1935–74

21 January 2018

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

Multiple myeloma in elderly patients: prognostic factors and outcome

21 January 2018

1 reference

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

Multiple myeloma in elderly patients: presenting features and outcome

21 January 2018

1 reference

Treatment strategies in elderly patients with multiple myeloma: current status

21 January 2018

1 reference

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

21 January 2018

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

21 January 2018

1 reference

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

21 January 2018

1 reference

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

21 January 2018

1 reference

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

21 January 2018

1 reference

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

21 January 2018

1 reference

Autologous stem cell transplantation beyond 60 years of age.

21 January 2018

1 reference

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

21 January 2018

1 reference

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

21 January 2018

1 reference

Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients

21 January 2018

1 reference

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

21 January 2018

1 reference

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

21 January 2018

1 reference

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

21 January 2018

1 reference

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

21 January 2018

1 reference

A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma

21 January 2018

1 reference

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

21 January 2018

1 reference

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

21 January 2018

1 reference

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

21 January 2018

1 reference

High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

21 January 2018

1 reference

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

21 January 2018

1 reference

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

21 January 2018

1 reference

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

21 January 2018

1 reference

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

21 January 2018

1 reference

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

21 January 2018

1 reference

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960

21 January 2018

1 reference

Erratum: International uniform response criteria for multiple myeloma

21 January 2018

1 reference

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.11.18

1 reference

24 August 2017

1 reference